Literature DB >> 21181497

In vitro susceptibility of a large collection of Candida Strains against fluconazole and voriconazole by using the CLSI disk diffusion assay.

Ana Carolina Azevedo1, Fernando César Bizerra, Daniel Arquimedes da Matta, Leila Paula de Almeida, Robert Rosas, Arnaldo Lopes Colombo.   

Abstract

We evaluated all Candida spp. isolates obtained from patients admitted to two tertiary care hospitals between 1999 and 2003 in the city of São Paulo, Brazil. The in vitro activities of fluconazole (FCZ) and voriconazole were determined by the agar disk diffusion test using the Clinical and Laboratory Standards Institute M44-A guidelines. The inhibition zone diameters were read and interpreted automatically by the BIOMIC(®) image-analysis plate reader system. We tested a total of 4,625 strains, including 2,393 strains of C. albicans (51.7%), 658 of C. tropicalis (14.2%), 503 of C. glabrata (10.9%), 495 of C. parapsilosis (10.7%), 292 of C. rugosa (6.3%), 195 of C. guilliermondii (4.2%) and 89 of other Candida species (2.0%). Only 2.0% of the strains tested were classified as dose-dependent susceptible (DDS), and 5.8% of them were resistant to FCZ. The resistance or DDS to fluconazole was verified mainly among C. glabrata (7.8%), C. krusei (67.9%) and C. rugosa (65.1%). Voriconazole exhibited better activity in vitro than fluconazole, even in isolates fluconazole resistant. The resistance of fluconazole and voriconazole did not increase in the isolates of Candida spp. during the evaluated period. © Springer Science+Business Media B.V. 2010

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21181497     DOI: 10.1007/s11046-010-9387-1

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  37 in total

1.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

2.  Trends and outcome of 1121 nosocomial bloodstream infections in intensive care units in a Brazilian hospital, 1999-2003.

Authors:  E Girão; A S Levin; M Basso; S Gobara; L B Gomes; E A S Medeiros; A A Barone; S F Costa
Journal:  Int J Infect Dis       Date:  2008-06-05       Impact factor: 3.623

3.  Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil.

Authors:  Valério Rodrigues Aquino; Luciano W Lunardi; Luciano Zubaran Goldani; Afonso Luis Barth
Journal:  Braz J Infect Dis       Date:  2006-01-06       Impact factor: 1.949

4.  Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; L Boyken; S A Messer; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program.

Authors:  Michael A Pfaller; Daniel J Diekema; David L Gibbs; Vance A Newell; Richard Barton; Hu Bijie; Jacques Bille; Shan-Chwen Chang; Maria da Luz Martins; Adriano Duse; Danuta Dzierzanowska; David Ellis; Jorge Finquelievich; Ian Gould; Deniz Gur; Anwar Hoosen; Kyungwon Lee; Nada Mallatova; Michele Mallie; N G Kee Peng; George Petrikos; Axel Santiago; Jan Trupl; Ann Marie VanDen Abeele; Jeannette Wadula; Mussaret Zaidi
Journal:  Diagn Microbiol Infect Dis       Date:  2010-03-24       Impact factor: 2.803

7.  Quality control limits for voriconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue.

Authors:  M A Pfaller; A Barry; J Bille; S Brown; D Ellis; J F Meis; R Rennie; M Rinaldi; T Rogers; M Traczewski
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

8.  Fluconazole susceptibility of Brazilian Candida isolates assessed by a disk diffusion method.

Authors:  Arnaldo L Colombo; Daniel Da Matta; Leila Paula De Almeida; Robert Rosas
Journal:  Braz J Infect Dis       Date:  2002-06       Impact factor: 1.949

9.  Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.

Authors:  Michael A Pfaller; Linda Boyken; Richard J Hollis; Jennifer Kroeger; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
Journal:  Diagn Microbiol Infect Dis       Date:  2009-09       Impact factor: 2.803

Review 10.  In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.

Authors:  A Espinel-Ingroff; K Boyle; D J Sheehan
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

View more
  8 in total

1.  Accurate identification of Candida parapsilosis (sensu lato) by use of mitochondrial DNA and real-time PCR.

Authors:  Ana Carolina R Souza; Renata C Ferreira; Sarah S Gonçalves; Guillermo Quindós; Elena Eraso; Fernando C Bizerra; Marcelo R S Briones; Arnaldo L Colombo
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  Multilaboratory study of the Biomic automated well-reading instrument versus MicroScan WalkAway for reading MicroScan antimicrobial susceptibility and identification panels.

Authors:  Robert C Fader; Emily Weaver; Rhonda Fossett; Michele Toyras; John Vanderlaan; David Gibbs; Andrew Wang; Nikolaus Thierjung
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948

3.  Antifungal activities of diphenyl diselenide alone and in combination with fluconazole or amphotericin B against Candida glabrata.

Authors:  Laura Bedin Denardi; Débora Alves Nunes Mario; Erico Silva de Loreto; Cristina Wayne Nogueira; Janio Morais Santurio; Sydney Hartz Alves
Journal:  Mycopathologia       Date:  2013-06-23       Impact factor: 2.574

4.  Inhibition of Phospholipase by Orlistat as an Alternate Therapy to Combat Opportunistic Mycosis Caused by C. albicans.

Authors:  Hardi Sinde; Priyanka Patel; Kunjan M Kikani; Dhyey R Kothari; Bhavtosh A Kikani
Journal:  Curr Microbiol       Date:  2021-04-03       Impact factor: 2.188

5.  Fluconazole susceptibility and ERG11 gene expression in vaginal candida species isolated from Lagos Nigeria.

Authors:  Victoria K Pam; Juliet U Akpan; Oyinlola O Oduyebo; Francisca O Nwaokorie; Muinah A Fowora; Rita O Oladele; Folasade T Ogunsola; Stella I Smith
Journal:  Int J Mol Epidemiol Genet       Date:  2012-02-25

6.  Isolation and drug susceptibility of Candida parapsilosis sensu lato and other species of C. parapsilosis complex from patients with blood stream infections and proposal of a novel LAMP identification method for the species.

Authors:  Plinio Trabasso; Tetsuhiro Matsuzawa; Renata Fagnani; Yasunori Muraosa; Kenichiro Tominaga; Mariangela Ribeiro Resende; Katsuhiko Kamei; Yuzuru Mikami; Angelica Zaninelli Schreiber; Maria Luiza Moretti
Journal:  Mycopathologia       Date:  2014-12-07       Impact factor: 2.574

7.  Isolation of Yeasts from Guajillo Pepper (Capsicum annuum L.) Fermentation and Study of Some Probiotic Characteristics.

Authors:  C E Lara-Hidalgo; L Dorantes-Álvarez; H Hernández-Sánchez; F Santoyo-Tepole; A Martínez-Torres; L Villa-Tanaca; C Hernández-Rodríguez
Journal:  Probiotics Antimicrob Proteins       Date:  2019-09       Impact factor: 4.609

8.  Nosocomial candidiasis in Rio de Janeiro State: Distribution and fluconazole susceptibility profile.

Authors:  Paulo Murillo Neufeld; Marcia de Souza Carvalho Melhem; Maria Walderez Szeszs; Marcos Dornelas Ribeiro; Efigênia de Lourdes Teixeira Amorim; Manuela da Silva; Marcia dos Santos Lazéra
Journal:  Braz J Microbiol       Date:  2015-06-01       Impact factor: 2.476

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.